Radiopharmaceuticals are rapidly develo** as a field, with the successful use of targeted
beta emitters in neuroendocrine tumors and prostate cancer serving as catalysts. Targeted …

The high energy of α emitters, and the strong linear energy transfer that goes along with it,
lead to very efficient cell killing through DNA damage. Moreover, the degree of oxygenation …

Molecularly targeted radionuclide therapies (TRTs) struggle with balancing efficacy and
safety, as current strategies to increase tumor absorption often alter drug pharmacokinetics …

Objective. 225 Ac radiopharmaceuticals have tremendous potential for targeted alpha
therapy, however, 225 Ac (t 1/2= 9.9 d) lacks direct gamma emissions for in vivo imaging …

Purpose: Multiple myeloma is a plasma cell malignancy with an unmet clinical need for
improved imaging methods and therapeutics. Recently, we identified CD46 as an …

Abstract Rationale: 225 Ac, a long-lived α-emitter with a half-life of 9.92 days, has garnered
significant attention as a therapeutic radionuclide when coupled with monoclonal antibodies …

As theranostics is widely adopted, PRLT is safe and effective for reducing PSA and tumor
burden and improves survival in patients with mCRPC. Based on evidence and data …

(1) Background: In neuroendocrine tumors (NETs), somatostatin receptor subtype 2 is highly
expressed, which can be targeted by a radioactive ligand such as [177Lu] Lu-1, 4, 7, 10 …

Purpose The radionuclide pair cerium-134/lanthanum-134 (134Ce/134La) was recently
proposed as a suitable diagnostic counterpart for the therapeutic alpha-emitter actinium-225 …

Indium-111 (111In) is a diagnostic radiometal that is important in nuclear medicine for single-
photon emission computed tomography (SPECT). In order to apply this radiometal, it needs …